School of Korean Medicine, Pusan National University, Yangsan, Republic of Korea.
School of Korean Medicine, Pusan National University, Yangsan, Republic of Korea; Department of Korean Medicine Rehabilitation, Pusan National University, Korean Medicine Hospital, Yangsan, Republic of Korea.
Complement Ther Med. 2023 Nov;78:102991. doi: 10.1016/j.ctim.2023.102991. Epub 2023 Oct 5.
Migraine is a prevalent and disabling neurological disorder affecting a significant proportion of the global population. Although medications are the primary treatment option, their efficacy remains unclear. Thus, alternative therapies such as scalp acupuncture have gained momentum; however, evidence for the effectiveness of scalp acupuncture remains insufficient. Therefore, this review provides evidence regarding the effectiveness and safety of scalp acupuncture for the treatment of migraines.
PubMed, EMBASE, CENTRAL, Oriental Medicine Advanced Searching Integrated System, Korean Studies Information Service System, Korean Medical Database, NDSL, Citation Information by NII, and China National Knowledge Infrastructure were searched from their inception to September 2022 to identify randomised controlled trials (RCTs) without language restrictions. Data were collected and analysed independently by two reviewers. The RoB 2.0 tool was used to evaluate the risk of bias, and a meta-analysis was conducted using RevMan software (V5.4).
Eight RCTs including 874 patients were selected.
Scalp acupuncture had a higher total effective rate (relative risk [RR]:1.24; 95% confidence interval [CI]:1.08-1.43; P < 0.01) than that of ordinary acupuncture. The headache index decreased significantly (standardised mean differences [SMD]:-1.27; 95% CI:-2.06 to -0.48; P < 0.01), and the total effective rate was higher (RR:1.20; 95% CI:1.06-1.37; P < 0.01) with scalp acupuncture than with medications. However, evidence supporting the effectiveness of scalp acupuncture was not robust. No adverse events were reported.
Scalp acupuncture appears to be more effective than other treatments for migraines. However, their safety remains uncertain.
CRD42022348879.
偏头痛是一种常见且使人丧失能力的神经系统疾病，影响了全球很大一部分人口。尽管药物是主要的治疗选择，但它们的疗效仍不清楚。因此，头皮针刺等替代疗法受到了关注；然而，头皮针刺有效性的证据仍然不足。因此，本综述提供了有关头皮针刺治疗偏头痛的有效性和安全性的证据。
从成立之初到 2022 年 9 月，在 PubMed、EMBASE、CENTRAL、东方医学高级检索系统、韩国研究信息服务系统、韩国医学数据库、NDSL、NII 引文信息和中国国家知识基础设施中搜索了无语言限制的随机对照试验（RCT）。两位评审员独立收集和分析数据。使用 RoB 2.0 工具评估偏倚风险，并使用 RevMan 软件（V5.4）进行荟萃分析。
纳入的 8 项 RCT 共 874 例患者。
头皮针刺的总有效率（相对风险 [RR]：1.24；95%置信区间 [CI]：1.08-1.43；P<0.01）高于普通针刺。头痛指数明显降低（标准化均数差 [SMD]：-1.27；95% CI：-2.06 至 -0.48；P<0.01），头皮针刺的总有效率（RR：1.20；95% CI：1.06-1.37；P<0.01）高于药物。然而，支持头皮针刺有效性的证据并不充分。未报告不良反应。
头皮针刺似乎比其他偏头痛治疗方法更有效。然而，其安全性仍不确定。
PROSPERO 注册号：CRD42022348879。
